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ABSTRACT
Background: Hypertensive disorders of pregnancy impact over 10% of pregnancies
worldwide, while increasing the risk of low birth weight. Research is conflicting on
the effect of nutrient supplementation on hypertension during pregnancy. The cutoffs
to define hypertension have also recently changed to include a lower systolic blood
pressure, and little research has examined the association between the newly proposed
blood pressure cutoffs and low birth weight.
Objectives: Our objectives were to 1) evaluate the impact of prenatal lipid-based
nutrient supplement consumption on maternal blood pressure; and 2) assess the
association between maternal blood pressure during early and late pregnancy with
infant birth weight.
Study Design: A total of 1320 pregnant women ≤ 20 weeks gestation in Ghana were
randomized to receive daily either: 1) iron and folic acid, 2) multiple micronutrients,
or 3) a small-quantity lipid-based nutrient supplement. Gestational age was determined
by ultrasound and newborn weight measured at delivery. Blood pressure was
measured at enrollment and 36 weeks gestation. The effect of the consumption of a
lipid-based nutrient supplement on maternal blood pressure was analyzed using
ANOVA and ANCOVA, and associations between maternal hypertension and birth
weight were examined by linear and logistic regressions.
Results: Mean (±SD) systolic and diastolic blood pressure at 36 weeks gestation were
110±11 and 63±8 mmHg, respectively. The means for systolic and diastolic blood
pressure did not differ by supplementation group, (p-value>0.05). The prevalence of
high systolic blood pressure (≥ 130 mmHg) and high diastolic blood pressure (≥ 80

mmHg) at enrollment was 6.6% and 3.6% and there was a significant association
between higher diastolic blood pressure and lower birth weight at enrollment (! = 0.086, SE = 0.001 ; p = 0.011) in adjusted models. High diastolic blood pressure
significantly increased the risk for low birth weight (odds ratio = 2.99, 95%
confidence interval 1.04-8.62; p=0.042) in adjusted models. At 36 weeks, the
prevalence of high systolic and high diastolic blood pressure was 4.3% and 2.4% and
lower birth weight was significantly associated with higher systolic (! = -0.074, SE =
0.00 ; p = 0.029) and diastolic (! = -0.094, 0.00; p = 0.006) blood pressure. Diastolic
blood pressure was significantly associated with an increased risk of low birth weight
(OR=4.14, 95% CI=0.020).
Conclusions: Daily consumption of a lipid-based nutrient supplement during
pregnancy did not have a significant effect on maternal hypertension compared with
iron and folic acid or multiple micronutrients among women in Ghana. Both higher
systolic and higher diastolic blood pressure were associated with a lower birth weight,
although the association of diastolic blood pressure was larger in magnitude. Due to
the high rates of hypertension during pregnancy it is necessary to determine effective
strategies for prevention. Maternal hypertension may have implications for newborn
birth weight, and future research should determine blood pressure cutoffs specific to
pregnant populations that effectively identify pregnancies at risk for newborn low
birth weight.
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PREFACE
This thesis follows a manuscript format. The manuscript was prepared
following the guidelines for submission to the American Journal of Obstetrics and
Gynecology. This manuscript has yet to be submitted for review.
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Condensation: There was no significant effect of consumption of a lipid-based
nutrient supplement on hypertension during pregnancy. Maternal hypertension was
associated with newborn birth weight.
Short Title: Maternal BP in Relation to Birth Weight and the Effect of a Nutrient
Supplement
AJOG at a Glance:
A. Due to recent changes in blood pressure cut-offs, it remains unknown whether
prenatal lipid-based nutrient supplements affect blood pressure or whether
maternal hypertension is associated with newborn birth weight.
B. Adherence to a nutritional supplement was not associated with blood pressure,
and maternal hypertension was associated with birth weight.
C. Both high diastolic and high systolic blood pressure were significantly
associated with lower birth weight using the new blood pressure cut-offs.
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ABSTRACT
Background: Hypertensive disorders of pregnancy impact over 10% of pregnancies
worldwide, while increasing the risk of low birth weight. Research is conflicting on
the effect of nutrient supplementation on hypertension during pregnancy. The cutoffs
to define hypertension have also recently changed to include a lower systolic blood
pressure, and little research has examined the association between the newly proposed
blood pressure cutoffs and low birth weight.
Objectives: Our objectives were to 1) evaluate the impact of prenatal lipid-based
nutrient supplement consumption on maternal blood pressure; and 2) assess the
association between maternal blood pressure during early and late pregnancy with
infant birth weight.
Study Design: A total of 1320 pregnant women ≤ 20 weeks gestation in Ghana were
randomized to receive daily either: 1) iron and folic acid, 2) multiple micronutrients,
or 3) a small-quantity lipid-based nutrient supplement. Gestational age was determined
by ultrasound and newborn weight measured at delivery. Blood pressure was
measured at enrollment and 36 weeks gestation. The effect of the consumption of a
lipid-based nutrient supplement on maternal blood pressure was analyzed using
ANOVA and ANCOVA, and associations between maternal hypertension and birth
weight were examined by linear and logistic regressions.
Results: Mean (±SD) systolic and diastolic blood pressure at 36 weeks gestation were
110±11 and 63±8 mmHg, respectively. The means for systolic and diastolic blood
pressure did not differ by supplementation group, (p-value>0.05). The prevalence of
high systolic blood pressure (≥ 130 mmHg) and high diastolic blood pressure (≥ 80
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mmHg) at enrollment was 6.6% and 3.6% and there was a significant association
between higher diastolic blood pressure and lower birth weight at enrollment (! = 0.086, SE = 0.001 ; p = 0.011) in adjusted models. High diastolic blood pressure
significantly increased the risk for low birth weight (odds ratio = 2.99, 95%
confidence interval 1.04-8.62; p=0.042) in adjusted models. At 36 weeks, the
prevalence of high systolic and high diastolic blood pressure was 4.3% and 2.4% and
lower birth weight was significantly associated with higher systolic (! = -0.074, SE =
0.00 ; p = 0.029) and diastolic (! = -0.094, 0.00; p = 0.006) blood pressure. Diastolic
blood pressure was significantly associated with an increased risk of low birth weight
(OR=4.14, 95% CI=0.020).
Conclusions: Daily consumption of a lipid-based nutrient supplement during
pregnancy did not have a significant effect on maternal hypertension compared with
iron and folic acid or multiple micronutrients among women in Ghana. Both higher
systolic and higher diastolic blood pressure were associated with a lower birth weight,
although the association of diastolic blood pressure was larger in magnitude. Due to
the high rates of hypertension during pregnancy it is necessary to determine effective
strategies for prevention. Maternal hypertension may have implications for newborn
birth weight, and future research should determine blood pressure cutoffs specific to
pregnant populations that effectively identify pregnancies at risk for newborn low
birth weight.
Keywords: Ghana, low birth weight, maternal blood pressure, nutrient supplements,
pregnancy outcomes, prenatal supplementation
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INTRODUCTION
During a healthy pregnancy, blood pressure decreases from early to midpregnancy, increases in late pregnancy, and then returns to pre-pregnancy levels by
delivery.1 However, during pregnancy blood pressure may not change as expected, but
gradually rise and result in hypertension (HTN). HTN is defined as a systolic blood
pressure (SBP) ≥ 130 mmHg or diastolic blood pressure (DBP) ≥ 80 mmHg.2 The
definition was recently updated by the American Heart Association from an SBP ≥
140 mmHg or DBP ≥ 80 mmHg due to the increased risk for cardiovascular disease in
the general population.2 It is unclear if the new definition is appropriate for predicting
pregnancies at risk of adverse outcomes.
Ghana is a low-middle income country located in western Africa. Based on the
previous HTN cutoffs, over 20% of pregnancies in Ghana are impacted by HTN,3
compared to about 10% worldwide.4 The disparity may be related to lack of access to
adequate health care, a delay in seeking health care, or delayed response to maternal
health status at the health care facilities.5
Hypertensive disorders of pregnancy have been associated with increased risk for
low birth weight (LBW),6 which is defined as a newborn birth weight of < 2500
grams. LBW is associated with infections7 and trouble breathing8 for the infant, as
well as increased risk for diabetes and obesity,9 and intellectual and developmental
disabilities.10
Nutritional supplements may be an effective strategy to decrease the risk for
maternal HTN, especially since anti-hypertensive medication may increase the risk for
pregnancy complications.11, 12 Calcium supplementation daily has been associated with
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a decreased risk of maternal HTN, although evidence supports calcium
supplementation as only protective against HTN for women with low calcium intake.13
There is emerging evidence that lipids, specifically essential fatty acids (EFA), may
play a role in decreasing placental dysfunction and inflammation, and support
increased fetal growth.14, 15 However, EFAs have been associated with reduced risk of
maternal HTN and inflammatory markers only in animal studies. Larger intervention
studies in women have not found significant associations between EFA
supplementation or intake and maternal HTN.16 Research on nutrient supplementation
including EFAs that may decrease the risk of maternal HTN in human populations is
needed.
Our objectives were to 1) evaluate the impact of prenatal lipid-based nutrient
supplement (LNS) consumption on maternal blood pressure; and 2) assess the
association between maternal HTN during early and late pregnancy and newborn birth
weight using the new blood pressure cutoffs.

MATERIALS AND METHODS
Study Design
This is a secondary data analysis of the International Lipid-Based Nutrient
Supplements (iLiNS) Project; a randomized controlled trial. The research team
recruited pregnant women attending select prenatal clinics in the Eastern region of
Ghana, to determine the effects of nutrient supplements during pregnancy and the first
eighteen months of the newborn’s early childhood. For this analysis, data collected
from early pregnancy through birth will be used. LNS is a paste designed to be mixed
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with local foods, such as maize, cassava, rice, fish, and leafy vegetables, to increase
the nutrient and energy content for enrolled Ghanaian women during pregnancy and
lactation. Multiple micronutrient (MMN) and LNS supplements followed formulations
for United Nations Micronutrient Preparation (UNIMAP) previously used for prenatal
micronutrient supplementation in pilot programs among pregnant women.17 Nutriset
S.A.S. (Malaunay, France) produced the LNS in 20g sachets and Dutch State Mines
(DSM) South Africa (Kaiseraugst, Switzerland) produced the capsules of the iron and
folic acid (IFA) and MMN supplements. A more detailed description of the study
population and methods have previously been described.18
The iLiNS study protocol was approved by the institutional review boards at
the University of California, Davis; the Noguchi Memorial Institute for Medical
Research, University of Ghana; and the Ghana Health Service.
Participants
Eligibility for this study was specific to women attending prenatal clinics in
southern Ghana between December 2009 through December 2011, an age of at least
18 years old, and a gestational age of ≤ 20 weeks. Reasons for exclusion included a
test result that was HIV positive at baseline, a gestational age > 20 weeks, residence >
20 km outside of southern Ghana, history of peanut or milk allergies, severe illness, or
the intention to move within two years. Participants consented to screen for eligibility,
and if eligible, fieldworkers collected anthropometrics and baseline lab values.
A randomization scheme was designed by a study statistician. Each woman
was randomized into either the IFA, MMN, or LNS group. To ensure blinding, an
independent party from the research team color-coded supplement capsules of the IFA
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and MMN groups to blind investigators, fieldworkers, and participants. Fieldworkers
were not aware of the group allocations, and data analysts were blinded until the
completion of preliminary analyses
Procedures
At enrollment, the research group distributed surveys to participants and
collected demographic characteristics and lab data. The research group collected lab
data again at 36 weeks gestation and newborn anthropometric measurements at
delivery.
At enrollment, fieldworkers distributed a two week supply of the assigned
supplement along with instructions on consumption methods. At bi-weekly, in-home
follow-ups with each participant, data on supplement adherence and morbidity, as well
as any remaining supplement were collected. Fieldworkers visited the home or
hospital at delivery to collect anthropometric measurements of newborns. For 91% of
infants, measurements were recorded within 48hrs of birth. Measurements for 9% of
infants were not available after 48hrs, and so measurements were collected between 314 days after birth.
Primary Outcomes and Definitions
Our primary outcomes to determine the effect of a nutrition supplement on
maternal hypertension are mean SBP and mean DBP at enrollment and 36 weeks
gestation. Our primary outcome to determine the association between maternal HTN
and birth weight is mean newborn birth weight. High SBP was defined as ≥130 mmHg
and high DBP as ≥80 mmHg. Consistent with the iLiNS study, for age- and sexstandardization of blood pressure and weight, the WHO 2006 multi-center growth
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standard was used.19 If the baby was measured within 48 hours, birth weight is
reported in grams. If after 48 hours, adjustments for weight following the main iLiNS
study were employed.
Statistical Analysis - Effect of LNS on Maternal HTN
In this randomized study design, quantifying the as-treated effect of LNS on
maternal hypertension was of primary interest. During the study, IFA and MMN
capsules were unintentionally mislabeled, causing 92 participants in the IFA group
and 85 participants in the MMN group to receive the incorrect supplement. Therefore,
this analysis used the supplement treatment assignment actually received and not the
treatment originally assigned. A total of 86 women not-exposed in the LNS group, as
well as the mixed-exposure women in the IFA or MMN groups were excluded.
The main iLiNS trail included a total sample size of 1,057 (excluding women
pregnant during mixed exposure), where IFA = 349, MMN = 354, and LNS = 354.
Our sample size for each group is consistent with the main iLiNS trial and included
the total sample size of 1,057. All tests were two-sided, at a 5% level of significance.
Residuals were assessed for normality using a Shapiro-Wilk statistic. Prepregnancy body mass index (BMI), C-reactive protein (CRP) at enrollment, and α1acid glycoprotein (AGP) at enrollment were not normally distributed and were
logarithmically transformed for analysis. The heteroscedasticity assumption was also
examined through the plots and no outliers were identified through visual
identification in histograms or scatterplots.
Variables that were possible confounds and had a statistically significant
association with the outcome (p<0.1 in univariate models) were included in an
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adjusted regression model. To avoid collinearity, variables were considered in the
separate logistic regression models to assess the effect of the intervention on maternal
blood pressure. If a variable was significantly associated with the effect of the
intervention, logistic regression was used to determine if the effect of LNS on blood
pressure was significantly different between groups. The null-hypothesis was rejected
at the 0.05 level.
Linear regression was used to estimate the study intervention effects on blood
pressure. For the continuous outcomes, the difference between the three group means
was tested with ANOVA and ANCOVA models. If the null-hypothesis was rejected at
the 0.05 level, post-hoc pairwise comparisons across the three intervention groups was
tested using the Benjamini-Hochberg procedure to adjust for multiple comparisons.20
Due to the number of participants exposed to the incorrect supplement, a
sensitivity analysis was conducted to determine if the exclusion of those women
influenced the results. The analyses determining the effect of LNS on maternal HTN
was repeated with all participants included.
Statistical Analysis - Association Between Maternal HTN and Birth Weight
We evaluated normality of the residuals using a Shapiro-Wilk statistic. The
distributions of pre-pregnancy BMI, CRP and AGP at enrollment had deviations from
normality, and were logarithmically transformed for analysis. The heteroscedasticity
assumption was examined through the residual versus fit plot. A scatterplot between
the independent and dependent variables was visually examined to check that the
relationship between the predictor and response was linear. No outliers were visually
identified through histograms or scatterplots.
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The covariates recorded at enrollment that had a statistically significant
association with the outcome (p<0.1) were included in adjusted regression models. For
continuous predictors, collinearity was checked by running models with covariates and
an examination of variance inflation factors (VIF). VIF above 10 was considered
problematic, however, there were no variables that exceeded a VIF of two. Therefore,
there was no evidence of collinearity and all variables significantly associated with the
outcome were included in adjusted models.
Continuous variables were analyzed with linear regression if they were
determined to have a statistically significant association with the outcome. Multiple
linear regression models were used to determine the association between systolic and
diastolic blood pressure and birth weight.
RESULTS
The total sample size used in this analysis included 1,057 pregnant women,
with a 19% loss to follow up. There were 349 women included in the IFA group, 354
in MMN and 354 included in the LNS group. Means (±#$) and percentages of
maternal characteristics at enrollment for the IFA, MMN and LNS groups are shown
in Table 2, as well as the geometric mean and 95% confidence interval (CI) for CRP
and AGP. The prevalence of HTN at 36 weeks gestation was 5.3% (SBP ≥ 130 mmHg
or DBP ≥ 80 mmHg). The prevalence of high SBP at 36 weeks gestation was 4.3%
and high DBP was 2.4%.
Supplement Group Comparisons
Table 3 shows the mean SBP and DBP at 36 weeks gestation by supplement
group. The unadjusted and adjusted means of SBP and DBP at 36 weeks gestation
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were not significantly different between groups (p>0.05). Maternal age modified the
effect of the intervention on maternal SBP at 36 weeks; F(2, 1054) = 3.40, (p-value for
interaction = 0.034). Maternal age was categorized into high and low age groups using
the median, and the effect of the intervention on maternal SBP at 36 weeks was no
longer significant, F(2,1054) = 1.40, (p-interaction = 0.246). There were no significant
differences in risk for maternal HTN between IFA or MMN and LNS (table 4).
In the sensitivity analysis including all women (exposed and not exposed)
neither SBP or DBP means significantly differed by supplementation group in
unadjusted or adjusted analysis.
Maternal BP and Newborn Birth Weight.
Table 5 presents the characteristics of total, normal, and HTN groups at
enrollment. Women with HTN had a significantly higher age, pre-pregnancy BMI,
height, SBP and DBP compared to those with normal blood pressure; (p<0.05).
At enrollment, SBP was not significantly associated with a lower birth weight
in unadjusted or adjusted models determining standardized beta (!) coefficients (table
6). Similarly, high SBP did not significantly increase the risk for LBW (Table 7).
However, as opposed to SBP, DBP at enrollment was significantly associated with a
lower birth weight in adjusted models and remained significant after the BenjaminiHochberg procedure (! = -0.086, SE = 0.001 ; p = 0.011). High DBP at enrollment
significantly increased the risk for LBW (odds ratio (OR) = 2.99, 95% confidence
interval (95% CI)= 1.04-8.62; p=0.042) when adjusting for pre-pregnancy BMI,
maternal age, height, assets index, parity, hemoglobin, offspring sex, and treatment
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group, SBP and DBP at enrollment. However, after the Benjamini-Hochberg
Procedure it was no longer statistically significant (p=0.064).
Unlike early pregnancy, at 36 weeks gestation, higher SBP was significantly
associated with a lower birth weight in adjusted models (! = -0.074, SE = 0.00 ; p =
0.029). High SBP did not significantly decrease the risk for LBW (OR=2.19, 95% CI
=0.72-6.73; p=0.170). Higher DBP was significantly associated with a lower infant
birth weight (! = -0.094, SE = 0.00 ; p = 0.006) and increased the risk of LBW to over
four times the risk of those with normal blood pressure (OR=4.14, 95% CI=0.020).
DISCUSSION
In this study, higher DBP presented a strong association with lower newborn
birth weight at enrollment and 36 weeks gestation. SBP was only significantly
associated with a lower birth weight at 36 weeks gestation, and only DBP significantly
decreased the risk for LBW. LNS did not significantly decrease the risk for maternal
hypertension compared to IFA or MMN.
The association between higher DBP and a lower birth weight, and LNS not
significantly decreasing maternal blood pressure is consistent with previous research
using the previous blood pressure cutoffs. In a study by Bakker et al. (2011), higher
DBP had stronger associations with a lower birth weight compared to SBP, as well as
an increased risk for LBW.21 A randomized control trial conducted in Bangladesh
found no significant associations between LNS and maternal blood pressure.22
Our findings that HTN is associated with LBW may be explained by maternal
HTN leading to reduced placental perfusion,23 placental dysfunction, and increased
inflammation.14 Inflammation may lead to fetal hypoxia that may inhibit fetal growth,
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and thereby reduce newborn birth weight.24 Alternatively, maternal HTN may actually
be a consequence of fetal growth restriction, as fetal growth restriction and placental
dysfunction may decrease placental vasodilators, which are increasingly important
during late pregnancy for blood pressure maintenance.25 The underlying mechanisms
for how maternal blood pressure and birth weight are related remains unclear.
The functional differences between DBP and SBP may explain our findings
that DBP and SBP presented different associations with lower birth weight. DBP is
largely responsible for cardiac output 26 and the amount of blood flow that the placenta
and ultimately fetus may have access to.25 With increased DBP, there is decreased
cardiac output, leading to decreased blood flow to the placenta, resulting in less fetal
access to oxygen and nutrients required for growth.26
There are strengths and limitations of this study. Limitations to note include
missing information related to the use of anti-hypertensive medications, which may
affect newborn birth weight. However, we were able to control for all women with a
history of HTN prior to pregnancy, which would include those with a history of taking
anti-hypertensive medication. That analysis examined women as a cohort, therefore,
we are unable to attribute the causation of LBW to maternal HTN. This study also has
many strengths including a low loss to follow-up and the reliability of methods.
Specifically, ultrasound scans were used to determine gestational age, and both blood
pressure measurements and newborn birth weight were measured by trained
fieldworkers.
Due to the high rates of HTN during pregnancy and considering the health
disparities that exist in developing countries, it is necessary to determine effective
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strategies for prevention. Research determining the effect of essential fatty acid
supplementation on maternal HTN in human populations is needed. Maternal HTN
may have implications for newborn birth weight, and future research should determine
blood pressure cutoffs specific to pregnant populations that effectively identify
pregnancies at risk for newborn LBW.
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TABLES
Table 1: Composition of supplements given to pregnant Ghanaian women recruited
between 2009-2011 in the International Lipid-Based Nutrient Supplements (iLiNS)
Project Study.

Nutrient
Ration, g/d
Total Energy, kcal
Protein, g
Fat, g
Linoleic acid, g
a-Linolenic acid, g
Vitamin A, 'g RE
Vitamin C, mg
Vitamin B-1, mg
Vitamin B-2, mg
Niacin, mg
Folic acid, 'g
Pantothenic acid, mg
Vitamin V-6, mg
Vitamin B-12, 'g
Vitamin D, IU
Vitamin E, mg
Vitamin K, 'g
Iron, mg
Zinc, mg
Copper, mg
Calcium, mg
Phosphorus, mg
Potassium, mg
Magnesium, mg
Selenium, 'g
Iodine, 'g
Manganese, mg

IFA

400

60

MMN
1 tablet
0
0
0
0
0
800
100
2.8
2.8
36
400
7
3.8
5.2
400
20
45
20
30
4
0
0
0
0
130
250
2.6

LNS
20
118
2.6
10
4.59
0.59
800
100
2.8
2.8
36
400
7
3.8
5.2
400
20
45
20
30
4
280
190
200
65
130
250
2.6

Iron and folic acid (IFA capsule is standard practice and follows WHO and Ghana
Health Service recommendation; multiple micronutrient supplement (MMN) capsule;
lipid-based nutrient supplement (LNS) for pregnant and lactating women
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Table 2: Characteristics at enrollment of pregnant Ghanaian women enrolled in the
International Lipid-Based Nutrient Supplements (iLiNS) Project Study.

Characteristic
Maternal Age
Gestational
Age
Parity
Parous
BMI
Height, cm
Education,
completed
years
Married or
Cohabitating
Offspring Sex
Female
CRP*
AGP*
Mean SBP
Mean DBP
Positive
Malaria test

IFA, n=349

Mean (SD) or %
MMN, n=354

LNS, n=354

26.5 (5)

26.9 (6)

26.5 (5)

16.3 (3)

16.2 (3)

16.22 (3)

62%
24.5 (4)
158.5 (6)

69%
24.4 (4)
159.1 (6)

64%
24.7 (4)
159.0 (5)

7.6 (4)

7.5 (4)

7.7 (4)

92%

94%

93%

49%
3.8 (3.3-4.3)
0.6 (0.6-0.7)
112 (10)
63 (7)

51%
3.13 (2.78-3.52)
0.6 (0.6-0.6)
111 (12)
64 (8)

49%
3.32 (2.92-3.79)
0.6 (0.6-0.6)
112 (11)
64.33 (8)

9%

8%

11%

*Geometric mean and 95% Cl presented

Abbreviations: IFA, iron and folic acid: capsule is standard practice and follows WHO
and Ghana Health Service recommendation; MMN, multiple micronutrient
supplement capsule; LNS, lipid-based nutrient supplement for pregnant and lactating
women; BMI, body mass index; CRP, C-reactive protein; AGP, α1-acid glycoprotein;
SBP, systolic blood pressure; DBP, diastolic blood pressure.
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Table 3: Mean systolic and diastolic blood pressure at 36 weeks gestation by
supplement group in pregnant Ghanaian women of International Lipid-Based Nutrient
Supplements (iLiNS) Project Study

IFA
n=349
Mean
(95%CI)

MMN
n=354
Mean (95%
CI)

LNS
n=354
Mean (95%
CI)

109.9
(108.9-111.0)

109.5
(108.3-110.7)

110.2
(109.0-111.4)

0.704

109.9
(108.9-111.0)

109.6
(108.4-110.8)

110.3
(109.1-111.5)

0.958

62.8
(62.0-63.6)

62.2
(61.4-63.0)

63.1
(62.3-63.9)

0.266

62.8
(62.0-63.6)

62.3
(61.4-63.0)

63.1
(62.3-63.9)

0.668

p

Unadjusted
SBP
Adjusted SBP
Unadjusted
DBP
Adjusted DBP

Abbreviations: IFA, iron and folic acid: capsule is standard practice and follows WHO
and Ghana Health Service recommendation; MMN, multiple micronutrient
supplement capsule; LNS, lipid-based nutrient supplement for pregnant and lactating
women; SBP, systolic blood pressure; DBP, diastolic blood pressure.
Adjusted models included pre-pregnancy BMI, gestational age, maternal age,
completed years of education, asset index, food insecurity index, hemoglobin status,
maternal height, CRP, AGP, parity, history of hypertension, and malaria status; all
covariates were ascertained at study enrollment.
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Table 4: Adjusted odds of high systolic or diastolic blood pressure at 36 weeks
gestation by supplement group in pregnant Ghanaian women of International LipidBased Nutrient Supplements (iLiNS) Project Study

IFA vs LNS
OR
95% CI

MMN vs LNS
OR
95% CI

Normal BP

1.00

-

1.00

-

High SBP (n=45)

0.63

0.27-1.47

0.87

0.40-1.91

High DBP (n=25)

0.56

0.19-1.67

0.93

0.33-2.61

Abbreviations: IFA, iron and folic acid: capsule is standard practice and follows WHO
and Ghana Health Service recommendation; MMN, multiple micronutrient
supplement capsule; LNS, lipid-based nutrient supplement for pregnant and lactating
women; SBP, systolic blood pressure; DBP, diastolic blood pressure.
Adjusted models included pre-pregnancy BMI, gestational age, maternal age,
completed years of education, asset index, food insecurity index, hemoglobin status,
maternal height, CRP, AGP, parity, history of hypertension, and malaria status; all
covariates were ascertained at study enrollment.
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Table 5: Characteristics of total, normal, and high blood pressure groups at enrollment
of pregnant Ghanaian women of the International Lipid-Based Nutrient Supplements
(iLiNS) Project Study.

Characteristic
Maternal Age
Gestational Age
Parity
Parous
BMI
Height
Education,
completed years
Married or
cohabitating
Offspring Sex
Female
CRP
AGP
SBP
DBP
Positive Malaria
test

Total
(n=1057)
Mean (SD)
or %

Normal BP
Group
(n=1001)
Mean (SD) or
%

HTN Group
(n=56)
Mean (SD) or
%

26.7 (5)
16.2 (3)

26.6 (5)
16.2 (3)

28.6 (6)
16.3 (3)

65%
24.5 (4)
158.9 (6)
7.6 (3)

65%
24.3 (4)
158.8 (6)
7.6 (4)

73%
28.6 (6)
160.5 (6)
7.7 (4)

<0.001
0.023
0.833

93%

93%

93%

0.989

p
0.007
0.857
0.190

0.496
50%
3.39 (3.2-3.7)
0.6 (0.6-0.6)
112 (11)

50%
3.36 (3.1-3.6)
0.6 (0.6-0.6)
110 (10)

45%
4.75 (3.4-6.6)
0.7 (0.6-0.7)
135 (9)

0.092
0.089
<0.001

64 (8)

63 (7)

80 (8)

<0.001

10%

10%

10%

0.782

*Geometric mean and 95% Cl presented
Abbreviations: BMI, body mass index; CRP, C-reactive protein; AGP, α1-acid
glycoprotein; SBP, systolic blood pressure; DBP, diastolic blood pressure; BP, blood
pressure; HTN, hypertension- SBP ≥ 130 mmHg or DBP ≥ 80 mmHg
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Table 6: Unadjusted and adjusted beta (!) coefficients of systolic and diastolic blood
pressure predictors at enrollment and 36 weeks gestation and newborn birth weight in
the International Lipid-Based Nutrient Supplements (iLiNS) Project Study.
Birth Weight, g
! (SE)

Unadjusted

Adjusted

0.056 (0.001)

-0.062 (0.001)

0.087

0.066

0.039 (0.001)

-0.086 (0.001)

0.230

0.011*

0.054 (0.001)

-0.074 (0.001)

0.101

0.029*

0.043 (0.001)

-0.094 (0.001)

BP at Enrollment
SBP (mmHg)
p
DBP (mmHg)
p
BP at 36wks
SBP (mmHg)
p
DBP (mmHg)
p

0.192
0.006*
*significant after Benjamini-Hochberg procedure
Abbreviations: SBP, systolic blood pressure; DBP, diastolic blood pressure; BP, blood
pressure. p = p-value at 0.05 significance level.
Adjusted models included pre-pregnancy BMI, maternal age, asset index, parity,
hemoglobin status, offspring sex, maternal height, and treatment group; all covariates
were ascertained at study enrollment.
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Table 7. Adjusted odds of low birth weight (LBW) predicted by maternal blood
pressure (BP) at enrollment an 36 weeks gestation in the International Lipid-Based
Nutrient Supplements (iLiNS) Project Study

LBW
(n=93)

OR
BP at Enrollment
Normal BP
(n=987)
High SBP
(n=70)
High DBP
(n=38)
BP at 36wks
Normal BP
(n=1012)
High SBP
(n=45)
High DBP
(n=25)

95% CI

p

1.00

-

-

1.04

0.35-3.06

0.948

2.99

1.04-8.62

0.042†

1.00

-

-

2.19

0.72-6.73

0.170

4.14

1.26-13.62

0.020*

*significant after Benjamini-Hochberg procedure
†not significant after Benjamini-Hochberg procedure
Abbreviations: SBP, systolic blood pressure; DBP, diastolic blood pressure; BP, blood
pressure; normal SBP < 130mmHg; high SBP ≥ 130 mmHg; normal DBP < 80mmHg;
high DBP ≥ 80 mmHg; LBW, low birth weight – infant born < 2500 grams.
Adjusted models included pre-pregnancy BMI, maternal age, asset index, parity,
hemoglobin status, offspring sex, maternal height, and treatment group; all recorded at
enrollment.
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CHAPTER 2
REVIEW OF LITERATURE

Introduction
Over 10% of pregnancies are impacted by high blood pressure (HTN)1 which
is currently defined as systolic blood pressure (SBP) ≥ 130 mmHg or diastolic blood
pressure (DBP) ≥ 80 mmHg.2 Maternal HTN is associated with adverse pregnancy and
birth outcomes, including increased risk for chronic disease and an infant born with a
low birth weight (LBW). 3 To reduce the prevalence of HTN in pregnant populations,
current nutrient recommendations are limited to an increase of dietary calcium to one
gram daily, with conflicting evidence related to the effect of supplementing additional
nutrients to decrease maternal blood pressure.4
There are various disorders during pregnancy related to high blood pressure,
including preeclampsia (PE), gestational hypertension (GH), and chronic
hypertension. PE is a hypertensive disorder of pregnancy that includes proteinuria, in a
previously normotensive woman.5 GH is an SBP ≥ 130 mmHg or DBP ≥ 80 mmHg
recorded on two separate occasions during pregnancy or after 20 weeks gestation.
Chronic hypertension is diagnosed prior to pregnancy or before 20 weeks gestation.

Maternal Blood Pressure
Blood pressure fluctuations during pregnancy are normal and expected.6 On
average, in normal pregnancies, SBP decreases to 112 mmHg, and DBP decreases to
65 mmHg by 12 weeks gestation.6 By late pregnancy, around 37 weeks gestation, both
SBP and DBP increase to 116 and 70 mmHg.6,7 These fluctuations in blood pressure
result from the blood supply requirements for normal development of the fetus,8,9 as
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well as hormonal influences on vascular remodeling .10,11 However, there are many
risk factors for maternal HTN. Among others, risk factors for maternal HTN include
maternal age,12 chronic hypertension and a history of preeclampsia.13
Maternal HTN is associated with complications during pregnancy as well an
increased risk for long-term chronic disease. The overall risk for maternal mortality
increases, as well as an increase in risk for maternal morbidity; specifically, the risks
for cardiovascular disease, kidney disease, diabetes and chronic hypertension is
increased.14-18 Maternal HTN significantly increases the risk (or hazard) by 44% to
300% for ischemic heart disease, myocardial infarcts, myocardial infarct death, heart
failure, ischemic stroke, kidney disease, and diabetes mellitus.14 Although maternal
HTN factors may be related to pre-pregnancy cardiovascular risk factors,19 there are
significant associations between hypertensive disorders of pregnancy and
cardiovascular risk factors, including a greater BMI, higher SBP and DBP, and
elevated levels of insulin and triglycerides.20
A strategy to decrease maternal HTN includes the use of antihypertensive
medication, although it is recommended that antihypertensive medication should only
be prescribed with an SBP ≥ 160 mmHg or DBP ≥ 110 mmHg due to increased risk
for pregnancy complications.21,22 This is in part due to the fact that all drugs for the
treatment of high blood pressure during pregnancy cross the placenta.23 The
consequences of this may include uteroplacental perfusion and maternal
hepatotoxicity.24 The American Heart Association also specifically discourages the
use of angiotensin-converting–enzyme (ACE) inhibitors and angiotensin II receptor
blockers (ARB) due to their association with adverse fetal and birth outcomes.25-27
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However, despite recommendations, antihypertensive medication is increasingly being
relied upon during pregnancy.28 For instance, in a review of antihypertensive
medication use during pregnancy in a Medicaid population, the overall use increased
almost 50% within six years, resulting in nearly 5% of pregnancies ultimately exposed
to antihypertensive medication. Furthermore, participants were unlikely to switch to
recommended antihypertensive medications, and continued with medications
associated with increased risk for adverse outcomes.28
The prevalence and impact of high maternal blood pressure may impact
developing countries to a greater degree than developed countries. To be specific, in
Ghana, over 19% of pregnancy-related deaths are related to hypertensive disorders of
pregnancy,29 compared to the 7.4% in the United States.30 The disparity may be
related to lack of access to or a delay in seeking health care, or delayed response to
maternal health status at the health care facilities.31 In developing countries, there may
also be limited ability to screen for hypertensive disorders, specifically in rural
settings.32 Additionally, in Ghana it is estimated that nearly 43% of Ghanaian adults
are obese, with an estimated 27.8% of women being overweight and 21.9% obese.33
With this in mind, a cohort study conducted in Ghana by Amoakoh-Coleman et al.
(2017),34 determined that women who were obese had three times the risk of
gestational hypertension compared to pregnant women with a normal BMI (RR 3.01,
95% CI: 1.06 – 8.52; p=0.04). However, this study had many limitations in that weight
was not based on pre-pregnancy weight, but was measured at 20 weeks gestation.
Another limitation was that women were excluded from the study if they were
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previously diagnosed with hypertension at baseline; this may result in an
underestimation of the risk of gestational hypertension.
The underlying mechanisms for causes of maternal HTN remains unclear;
however, hypertensive disorders of pregnancy may result from reduced uterine
perfusion, placental dysfunction, genetic polymorphisms, and immune
maladaptation,35 as well as their relationship with endothelial dysfunction. In animal
studies, there is also evidence that a reduction of uterine perfusion pressure influences
the distribution of a peptide receptor produced by the vascular endothelium,
endothelin receptor type-B, which decreases vasodilatation and enhances
vasoconstriction.36 Decreases in vasodilatation and enhanced vasoconstriction will
increase the arterial pressure through increased arterial resistance resulting in an
increased blood pressure. For PE specifically, abnormal uteroplacental blood
circulation may lead to maternal endothelial dysfunction, ultimately resulting in
maternal HTN and proteinuria.37 In addition, increased inflammatory markers
including C-reactive protein, tumor necrosis factor-α and interleukin-6 may also been
associated with hypertensive disorders in pregnancy.38

Nutrients and Maternal Blood Pressure
As a whole, research determining the various independent causes of hypertensive
disorders of pregnancy are not totally understood, and as such, the relationship
between specific nutrient levels or intakes and maternal blood pressure remains
uncertain. This is highlighted in a prospective observational cohort study by Oken et
al. (2007),39 which examined the associations between gestational hypertension and,
among others, calcium, omega-3 fatty acids, magnesium, folate, and vitamins C, D,
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and E. Pregnant women included in the study were participants in Project Viva, with a
final sample size of 1718 women. Women completed questionnaires and interviews to
collect information related to maternal characteristics and dietary patterns. The study
determined that compared with women maintaining a normal blood pressure
throughout pregnancy, women with PE had a lower consumption of omega-3 fatty
acids, vitamin C, E, folate, and magnesium, while women with gestational
hypertension maintained higher dietary intakes of vitamins C, D, and E. However, the
risk for PE or gestational hypertension was not reduced, despite intake levels of
calcium or vitamin D. Furthermore, women only had a lower risk of PE with increased
levels of omega-3 fatty acids and magnesium. That study is just one example of how
specific nutrients may have independent associations with hypertensive disorders of
pregnancy; and often, the relationships are not as expected.
Calcium
One of the first descriptions of the relationship between calcium and high blood
pressure in pregnancy was due to the observation that pregnant, Guatemalan women
who were considered poor, had a low prevalence of eclampsia (0.4%) compared to
other developing countries (e.g. 12%, India), as well as developed countries (e.g.
Japan, 15%).40 That population also maintained high levels of calcium consumption
(1320 mg/day in urban settings) compared to the other countries (347 mg/day, India;
368 mg/day, Japan). A staple food in the Guatemalan diet that contributed high
amounts of calcium was maize tortillas, which were cooked and soaked in lime water
(calcium hydroxide). Similarly, in Ethiopia, a diet consisting of the grain, teff, and
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lime in meal preparation allowed for a daily consumption of ~1075 mg of calcium per
day. Meanwhile, the prevalence of eclampsia in Ethiopia was 0.9%.40
As research has progressed, calcium supplementation during pregnancy in
populations with inadequate calcium levels41 has been associated with a lower risk for
pregnancy complications such as maternal HTN, and adverse birth outcomes. A
suggested mechanism is derived from the association between increased calcium
intake and decreased parathyroid hormone (PTH). PTH plays a central role in calcium
homeostasis and blood pressure regulation. Low levels of calcium signal the
parathyroid glands to increase circulating PTH. Increased PTH increases
vasoconstriction, which ultimately raises blood pressure and signals the kidneys to
increase calcium reabsorption and phosphate excretion; as well as the stimulation of
bone resorption to increase calcium levels.42,43
Additional mechanisms to describe the relationship between calcium and
maternal blood pressure may include the regulation of hormones in addition to PTH,
such as calcitriol, a derivative of vitamin D, and calcitonin. High extracellular calcium
stimulates the release of calcitonin,44 which is a hormone produced in the thyroid
gland that opposes PTH and can function to increase vasodilation. Therefore,
calcitonin has an inverse relationship with blood pressure. Calcitonin gene-related
peptide (CGRP) is a member of the calcitonin family,45 and levels of CGRP
significantly increase throughout pregnancy, before returning to pre-pregnancy levels
post-delivery.46This is consistent with the inverse trajectory of maternal blood pressure
in healthy individuals, which decreases until mid-pregnancy and returns to normal
near delivery.6,7 Moreover, in a case-control study with pre-eclamptic women and
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matched normotensive women, CGRP was significantly lower in women with preeclampsia than controls between 21-29 weeks gestation (p<0.001).47 Hence, it is
suggested that increased extracellular calcium, which stimulates calcitonin, results in
vasodilation and decreased blood pressure. The reverse may also be true, in that
decreased calcium and lower calcitonin levels allows for vasoconstriction and
increased maternal blood pressure.
Currently, it is recommended that pregnant women with low calcium intake
supplement 1.5-2.0 grams of calcium daily, to decrease risk of HTN.3 However, while
calcium supplementation during pregnancy in populations with inadequate calcium
levels has been associated with a lower risk for maternal HTN,48 it remains uncertain
whether calcium supplementation may benefit women with adequate calcium intake.49
Vitamin D
Vitamin D is a fat-soluble vitamin, which can be present in the body in inactive
form (cholecalciferol). With UVB exposure through sunlight, inactive vitamin D can
be metabolized by the liver to calcidiol and converted by the kidneys to the active
form, calcitriol50 . In addition to endogenous sources, active vitamin D can be obtained
through nutrient supplements and dietary sources such as fish, mushrooms, and
fortified food products51 . For health promotion and disease prevention, adequate
levels of vitamin D for the general population are currently considered to be a
concentration of 75 nmol/L, while inadequate levels are < 50 nmol/L.52 In the United
States, it is estimated that > 30% of pregnant women maintain inadequate levels of
vitamin D,53 whereas only 1% of pregnant women in Tanzania are inadequate54 and
96% in India.55
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Research related to vitamin D that is of high quality and relatively reliable remains
limited, specifically within pregnant populations.56,57 Therefore, adequate intakes and
corresponding health impacts remain unclear.57 The consequences of a deficiency of
vitamin D may include an infant born with low birth weight, an infant born small for
gestational age,58 myopathy (muscle disease),59 and certain autoimmune diseases;
although the extent to which vitamin D impacts diseases independent of calcium
requires additional research60. During pregnancy, vitamin D has also been associated
with a decreased risk for maternal high blood pressure56 and involvement in calcium
maintenance homeostasis.61
Research is conflicting on mechanisms by which vitamin D may influence
maternal blood pressure.62,63 One mechanism includes the ability of vitamin D to
stimulate calcium absorption, transport and removal across intestinal cells,64 though
recent research indicates an inverse relationship between vitamin D and PTH.63 As
previously mentioned, PTH plays a central role in the calcium metabolic pathway and
blood pressure regulation, and decreased levels of vitamin D may increase PTH,
thereby increasing vasoconstriction. In a cross-sectional study by Garcia et al.
(2013),62 significant correlations in adjusted models were found between PTH and
SBP (r = 0.146; P = 0.010) and DBP (r = 0.126; P = 0.026) and PTH and vitamin D
status (r = −0.133; P = 0.019). However, associations between vitamin D status and
blood pressure were insignificant. Similarly, Hemmingway et al. (2018), found that
PTH decreased significantly in pregnant women with increasing vitamin D,
(P < 0.001), however there were no significant associations between elevated PTH and
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gestational hypertension or vitamin D deficiency and risk of gestational
hypertension.65
Sodium and Potassium
The American Heart Association recommends the restriction of sodium (Na) to <
1500 mg in the general population, and 2300 mg as the upper intake level to prevent
adverse health outcomes.66 This is because high sodium intake has been associated
with an increased risk for high blood pressure and cardiovascular disease in the
general population.67-69
One suggested mechanism linking sodium intake and increased blood pressure is
related to the regulation of extracellular fluid volume. In healthy adults, a renal arterial
pressure may signal the kidneys to either retain or excrete sodium in order to control
BP, called pressure natriuresis. However, with high sodium intake, the function of
hormones in the renin-angiotensin aldosterone system responding to sodium levels and
blood pressure may be impaired and result in dysregulation of the extracellular fluid
volume and concurrently vasoconstriction.70 Increased extracellular fluid volume and
vasoconstriction may result in increased blood pressure.71
One strategy that promotes a restriction of sodium is the dietary approaches to
reduce hypertension (DASH) diet, which promotes increased fruits, vegetables, whole
grains and the reduction of saturated fat and sodium.72 The DASH diet has been
associated with a reduced risk for HTN, as well as decrease mean blood pressure in
those with hypertension.73-75
While sodium restriction has been a popular strategy to prevent or treat
hypertensive disorders, research on sodium intake during pregnancy and the effects on
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blood pressure has long been conflicting.76 Similarly, a low-sodium diet during
pregnancy has not consistently been significantly associated with a decrease in risk for
maternal HTN, nor is it recommended to limit intake during pregnancy.77 In the
1960’s, for example, there was research to support that an increase in sodium intake to
as much as 10 grams per day may be used to reduce blood pressure in pre-eclamptic
patients.78 Later, in the 1990s, sodium intake was not associated with maternal BP, but
was associated with significantly reduced intakes of energy, protein, carbohydrates,
fat, Ca, Zn, Mg, Fe and cholesterol.79 More recently, a clinical study in Southeast Asia
found that increased salinity of drinking water was associated with increased maternal
blood pressure.80 On the other hand, a study by Inoue et al. (2016),81 found no
significant associations between urinary salt excretion and maternal BP in Japan.
Current research is also exploring the relationship between sodium and potassium
(K), and the ratio that may be most effective for BP reduction.82 Potassium is an
electrolyte that may influence sodium retention by signaling the kidneys, hormonal
activation and influence the function of vascular smooth muscle.83 An analysis of
NHANES data determined that higher sodium and lower potassium was associated
with increased SBP in non-pregnant persons.84 In a study by Yilmaz et al. (2017),85
pregnant women with pre-eclampsia in a low Na/K group had significantly lower
mean SBP and DBP (mmHg) levels (148.2 ± 8.9, 92.3 ± 6.2) compared to the mean of
the medium Na/K group (155.0 ± 9.1, 97.1 ± 9.5) or high Na/K (158.5 ± 12.2, 99.2 ±
8.57) group; (p=0.024, p=0.0002, respectively). While these studies do support a
significant association between a low Na/K ratio, further research is needed to
determine the relationship with BP in healthy, pregnant populations.
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In summary, the effect of sodium restriction to decrease maternal BP and to
prevent or treat hypertensive disorders during pregnancy is unclear. Further research is
needed on the mechanisms by which sodium impacts blood pressure, specifically
during pregnancy, as well as the impact of Potassium and various Na/K ratios.
Additional Nutrient Supplementation
Additional nutrients with limited research on their relationship with maternal
HTN include essential fatty acids (EFAs), folate, magnesium, antioxidants
(specifically vitamins E, C, and selenium), and zinc.
EFAs - Increased essential fatty acids are associated with a greater gestational
age and fewer preterm births.86-89 There is also emerging evidence that essential fatty
acids play a role in decreasing placental dysfunction and inflammation and support
fetal growth and neurological development. Although EFAs have been associated in
animal studies with reduced the risk of maternal HTN and inflammatory markers
possibly involved in the pathogenesis, research in human populations is limited.90,91
Larger intervention studies in women have not found significant associations between
EFA supplementation or intake and maternal HTN.92,93
Folate – Homocysteine is an amino acid that is associated with cardiovascular
disease,94 and has been associated with the risk for PE and vasoconstriction during
pregnancy. It may also increase inflammation and contribute to endothelial
dysfunction. Decreased folate concentrations may lead to elevated homocysteine
levels, thereby resulting in maternal HTN. In non-pregnant women with folate
deficiency, serum folate was inversely related to blood pressure.95 However, larger
meta-analysis have highlighted the conflicting outcomes of the research, and
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ultimately determined no difference in maternal risk for hypertensive disorders of
pregnancy as a result of folate levels.96
Magnesium - Although magnesium intake has been associated with reduced
instances of PE, in a double-blind interventional study with ~200 pregnant women,
magnesium supplementation was not significantly associated with maternal blood
pressure.97 This is consistent with systematic reviews concluding that there is
insufficient evidence to recommend maternal magnesium supplementation to prevent
maternal HTN.98 The underlying mechanism for how magnesium may influence
maternal blood pressure, also remains unclear.
Antioxidants - Antioxidants have been associated with endothelial dysfunction,
which has been suggested as a mechanism for maternal HTN. However, studies of the
supplementation of vitamins C or E or selenium, have found weak or insignificant
association with decreasing risk for PE or hypertensive disorders of pregnancy.99-102
Zinc - While increased zinc has been associated with decreased oxidation,103 it is
not recommended during pregnancy as a strategy to decrease the risk for maternal high
blood pressure. Much of the research related to zinc and maternal blood pressure is
inconclusive and largely conflicting.104
Dietary Patterns
There is limited research related to overall dietary patterns during pregnancy and
maternal BP. One well-known dietary pattern is the Mediterranean diet, which
emphasizes whole grains, plant-based foods such as fruits and vegetables, as well as
the incorporation of olive oil and fish.105 The Mediterranean diet has been associated
with decreased risk for HTN and cardiovascular disease in the general population,106
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although low adherence to a Mediterranean-style dietary pattern was not significantly
associated with PE or gestation hypertension in an observational study with 3,187
pregnant women.107 In addition, diet quality as assessed in Project Viva’s Alternate
Healthy Eating Index, was not associated with the risk for PE.108 However, in a study
with nearly 30,000 Norwegian, pregnant women,109 dietary patterns emphasizing
vegetables, plant foods and vegetable oils were associated with a decreased risk for
PE. In the same study, an increased risk for PE was found in dietary patterns
emphasizing processed meat, salty snacks, and sweet drinks.

Maternal Blood Pressure and Newborn Birth Weight
A birth outcome that may result from maternal HTN is an infant born with a
low birth weight (LBW). Regardless of whether the infant was born at term (~37
weeks gestation) or preterm, LBW is defined as newborn weight < 2500 grams
(~5.5lbs). In 2014, the World Health Organization (WHO) reported that nearly 15%
newborns worldwide are born with LBW.110 While some of the known risk factors for
LBW are non-modifiable, such as maternal age and ethnicity,111 modifiable risk
factors include infections, drug use, anemia, low maternal BMI and chronic maternal
undernutrition.111,112 Among other things, an infant born with LBW has increased risk
for coronary heart disease,113 impaired cognitive function,114 and non-insulin
dependent diabetes.115 As a result, in 2016, WHO set a goal of a 30% reduction in
newborns with LBW by the year 2025.116
The prevalence of low-birth weight in Sub-Saharan Africa, an area including
Ghana, is about 13%.110 To determine risk factors related to LBW in Ghana, a
retrospective cohort study with 6,900 participants by Kayode et al. (2014),117 was
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conducted, while controlling for the context of the community in which the mothers
resided. Living in a rural setting increased the risk of LBW (OR 1.43, 95% CI: 1.01–
2.01; p < 0.05), as well as living in a community with a high poverty level (OR 2.16,
95% CI: 1.29–3.61; p < 0.01). However, access to community health care services was
not significantly associated with the risk of LBW (OR 1.28, 95% CI: 0.87–1.87; p >
0.05).
The Generation R study is a population-based prospective cohort study,
conducted in the Netherlands with > 8,800 pregnant women.118 In an analysis of the
associations between blood pressure, fetal growth risk, and the risk of adverse birth
outcomes, a change in SBP from the second trimester to third trimester was
significantly associated with an increased risk for LBW (OR 1.25, 95% CI: 1.12 1.40). Furthermore, a change in DBP from the second to third increased the risk (OR
1.49, 95% CI: 1.34 – 1.67), as well as a change between the first and third trimester.
This study also found that women with gestational hypertension gave birth to infants
with lower birth weights () = -89 grams, 95% CI: -137 to - 41, p < 0.01, respectively),
and odds of LBW at 1.85 (95% CI: 1.15 – 2.97) compared to women with normal
blood pressure during pregnancy.
Maternal HTN has been associated with an increased risk for adverse birth
outcomes primarily in high-income populations. Aside from LBW, outcomes of
maternal HTN include increased risk of preterm,118-120 an infant born small for
gestational (SGA),120,121 with a small head circumference,118 or still birth.119,121 While
the underlying mechanisms for how maternal BP contributes to birth outcomes
remains unclear, mechanisms may involve maternal HTN leading to placental
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dysfunction, specifically reduced placental perfusion, and inflammation. Inflammation
may lead to fetal hypoxia that may inhibit fetal growth, as well as reduce gestational
age, and other pregnancy complications.86,122,123 Alternatively, one hypothesis is that
maternal HTN is actually a consequence of fetal growth restriction. This is based on
the idea that to compensate for reduced placental perfusion and decreased birth
weight, maternal blood pressure increases.124

Conclusion
As a whole, the etiology and underlying mechanisms of maternal high blood
pressure are not well understood, further complicated by the nature of individual
hypertensive disorders of pregnancy. To avoid risks associated with hypertensive
medication, nutrient supplementation to manage maternal blood pressure is of
increasing interest. However, research related to the effect of nutrient supplementation
or dietary patterns on maternal blood pressure is conflicting. Limitations to current
research include inconsistencies in the definitions and specifications of hypertensive
disorders, as well as the trimester and duration in which the supplement was being
administered. Furthermore, future research is needed to determine the most effective
dosages and underlying mechanisms of nutrient supplements to influence blood
pressure; specifically, for calcium, vitamin D, and sodium. Maternal blood pressure is
also associated with adverse birth outcomes, such as an infant born with a low birth
weight, which is associated with long-term chronic disease. Future research is needed
to elucidate the pathology of low birth weight caused by maternal high blood pressure.
In conclusion, maternal high blood pressure is a major challenge to public health
worldwide, and even more-so in developing countries.
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CHAPTER 3
EXTENDED METHODOLOGY
Study Setting
The iLiNS study was conducted in southern Ghana, in an area north of Accra,
within various semi-urban communities. These communities are primarily subsistence
farmers or petty traders, with access to electricity and a public supply of water. Ghana
is considered to be a low-middle income country, and residents of these specific
communities are not poor or rich by Ghanaian standards. Staple foods included in the
regular diet include maize, cassava, rice, fish, and leafy vegetables.
Study Design
This is a secondary data analysis of the International Lipid-Based Nutrient
Supplements (iLiNS) Project. iLiNS is a partially double-blind, parallel, randomized
controlled trial. The research team recruited pregnant women attending select prenatal
clinics, to determine the effects of nutrient supplements during pregnancy and the first
eighteen months of the newborn’s early childhood. For this analysis, data collected
from early pregnancy through birth will be used. A prenatal lipid-based nutrient
supplement (LNS) is a paste designed to be mixed with local food to increase the
nutrient and energy content for enrolled Ghanaian women during pregnancy and
lactation. Multiple micronutrients (MMN) and LNS supplements followed
formulations for United Nations Micronutrient Preparation (UNIMAP) previously
used in pilot programs among pregnant women.125 Nutriset S.A.S. (Malaunay, France)
produced the LNS in 20g sachets and Dutch State Mines (DSM) South Africa
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(Kaiseraugst, Switzerland) produced the capsules of the iron and folic acid (IFA) and
MMN supplements. A more detailed description of the study population and methods
have previously been described.126
The iLiNS study protocol was approved by the institutional review boards at
the University of California, Davis; the Noguchi Memorial Institute for Medical
Research, University of Ghana; and the Ghana Health Service.
Participants
Eligibility for this study was specific to women attending prenatal clinics, and
recruited between December 2009 through December 2011, an age of at least 18 years
old, and a gestational age of ≤ 20 weeks. Reasons for exclusion included a test result
that was HIV positive at baseline, a gestational age > 20 weeks, residence > 20 km
outside of southern Ghana, history of peanut or milk allergies, severe illness, or the
intention to move within two years. Participants consented to screen for eligibility, and
if eligible, fieldworkers collected anthropometrics and baseline lab values.
Randomization and Blinding
A randomization scheme was designed by a study statistician. Each woman
was randomized into either the IFA, MMN, or LNS group. The major steps of the
randomization process are as follows:
•

Computer-generation (SAS version 9.3) randomized women after baseline
assessments into one of three groups.

•

A total of 1,320 envelopes (one for each participant), were divided into three
groups, and organized into blocks of nine. A block of nine envelopes contained
three envelopes for IFA, three for MMN, and three for LNS.
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•

A nurse shuffled one block of nine envelopes, and the participant chose one
envelope to determine group allocation.

To ensure blinding, an independent party from the research team color-coded
supplement capsules of the IFA and MMN groups to blind investigators, fieldworkers,
and participants. This allowed for sole identification of the capsule to be by color and
not supplement content. During follow-up visits, fieldworkers received the colorcoded supplement allocations for the participants from the field supervisor. Since LNS
was not a capsule, fieldworkers and participants could not be blinded from
distinguishing between LNS and IFA or MMN. Fieldworkers were not aware of the
group allocations, and data analysts were blinded until the completion of preliminary
analyses.
Procedures
At enrollment, the research group distributed surveys to participants and
collected demographic characteristics and lab data. The research group collected lab
data again at 36 weeks gestation and newborn anthropometric measurements at
delivery.
At enrollment, fieldworkers distributed a two week supply of the assigned
supplement along with instructions on consumption methods. At bi-weekly, in-home
follow-ups with each participant, data on supplement adherence and morbidity, as well
as any remaining supplement were collected. Fieldworkers visited the home or
hospital at delivery to collect anthropometric measurements of newborns. For 91% of
infants, measurements were recorded within 48hrs of birth. Measurements for 9% of
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infants were not available after 48hrs, and so measurements were collected between 314 days after birth.
Primary Outcomes and Definitions
Our primary outcomes to determine the effect of a nutrition supplement on
maternal hypertension are mean SBP and mean DBP at enrollment and 36 weeks
gestation. Our primary outcome to determine the association between maternal HTN
and birth weight is mean newborn birth weight. High SBP was defined as ≥130 mmHg
and high DBP as ≥80 mmHg. Consistent with the iLiNS study, for age- and sexstandardization of blood pressure and weight, the WHO 2006 multi-center growth
standard was used.127 If the baby was measured within 48 hours, birth weight is
reported in grams. If after 48 hours, adjustments for weight following the main iLiNS
study were employed.
Statistical Analysis - Effect of LNS on Maternal HTN
In this randomized study design, quantifying the as-treated effect of LNS on
maternal hypertension was of primary interest. During the study, IFA and MMN
capsules were unintentionally mislabeled, causing 92 participants in the IFA group
and 85 participants in the MMN group to receive the incorrect supplement. Therefore,
this analysis used the supplement treatment assignment actually received and not the
treatment originally assigned. A total of 86 women not-exposed in the LNS group, as
well as the mixed-exposure women in the IFA or MMN groups were excluded.
The main iLiNS trail included a total sample size of 1,057 (excluding women
pregnant during mixed exposure), where IFA = 349, MMN = 354, and LNS = 354.
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Our sample size for each group is consistent with the main iLiNS trial and included
the total sample size of 1,057. All tests were two-sided, at a 5% level of significance.
Residuals were assessed for normality using a Shapiro-Wilk statistic. Prepregnancy body mass index (BMI), C-reactive protein (CRP) at enrollment and α1acid glycoprotein (AGP) at enrollment were not normally distributed and were
logarithmically transformed for analysis. The heteroscedasticity assumption was also
examined through the plots and no outliers were identified through visual
identification in histograms or scatterplots.
Variables that were possible confounders and had a statistically significant
association with the outcome (p<0.1 in univariate models) were included in an
adjusted regression model. The following potential confounders were considered: prepregnancy BMI, gestational age, maternal age, maternal education, assets index, food
insecurity score, hemoglobin, parity, history of hypertension, maternal height, CRP,
AGP, a positive malaria test, season at maternal enrollment (dry vs wet), marital
status, and offspring sex reported at birth.
To avoid collinearity, variables were considered in the separate logistic
regression models to assess the effect of the intervention on maternal blood pressure.
If a variable was significantly associated with the effect of the intervention, logistic
regression was used to determine if the effect of LNS on blood pressure was
significantly different between groups. The null-hypothesis was rejected at the 0.05
level.
Linear regression was used to estimate the study intervention effects on blood
pressure. For the continuous outcomes, the difference between the three group means
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was tested with ANOVA and ANCOVA models. If the null-hypothesis was rejected at
the 0.05 level, post-hoc pairwise comparisons across the three intervention groups was
tested using the Benjamini-Hochberg procedure to adjust for multiple comparisons.128
Due to the number of participants exposed to the incorrect supplement, a
sensitivity analysis was conducted to determine if the exclusion of those women
influenced the results. The analyses determining the effect of LNS on maternal HTN
was repeated with all participants included.
Statistical Analysis - Association between maternal blood pressure and birth weight
We evaluated normality of the residuals using a Shapiro-Wilk statistic. The
distributions of pre-pregnancy BMI, CRP and AGP at enrollment had deviations from
normality, and were logarithmically transformed for analysis. The heteroscedasticity
assumption was examined through the residual versus fit plot. A scatterplot between
the independent and dependent variables was visually examined to check that the
relationship between the predictor and response was linear. No outliers were visually
identified through histograms or scatterplots.
The covariates recorded at enrollment that had a statistically significant
association with the outcome (p<0.1) were included in adjusted regression models.
The covariates recorded at enrollment that were considered for inclusion in an
adjusted model are as follows: Pre-pregnancy BMI, gestational age, maternal age,
maternal education, assets index, food insecurity score, parity, season at maternal
enrollment (dry vs wet), hemoglobin, marital status, history of hypertension, offspring
sex, maternal height, CRP, AGP, positive Malaria test, and treatment group.
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For continuous predictors, collinearity was checked by running models with
covariates and an examination of variance inflation factors (VIF). VIF above 10 was
considered problematic, however, there were no variables that exceeded a VIF of two.
Therefore, there was no evidence of collinearity and all variables significantly
associated with the outcome were included in adjusted models.
Continuous variables were analyzed with linear regression if they were
determined to have a statistically significant association with the outcome. Multiple
linear regression models were used to determine the association between systolic and
diastolic blood pressure and birth weight.
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